

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-14. (CANCELED)

15. (CURRENTLY AMENDED) A method of regulating expression of CCR3 comprising providing to a human cell an inhibitor of a GATA 1, GATA 2, and/or GATA 3 transcription factor that binds at exon-1 in a human CCR3 gene.

16. (PREVIOUSLY AMENDED) The method of claim 15 wherein the inhibitor binds at a GATA binding site in exon-1.

17. (PREVIOUSLY AMENDED) The method of claim 16 wherein the GATA binding site comprises SEQ ID NO:16.

18. (PREVIOUSLY AMENDED) The method of claim 16 wherein the GATA binding site is at least one of SEQ ID NO:17, SEQ ID NO:18, or SEQ ID NO:19.

19-46. (CANCELED)

47. (PREVIOUSLY PRESENTED) The method of claim 15 wherein the cell is an eosinophil.

48. (PREVIOUSLY PRESENTED) The method of claim 15 wherein the inhibitor inhibits binding of at least one of GATA-1, GATA-2, GATA-3, C/EBP, or AML-1a to exon-1.

49. (PREVIOUSLY PRESENTED) The method of claim 15 regulating at least one of CCR3 gene stability or levels of mRNA.

50. (CURRENTLY AMENDED) A method of regulating expression of CCR3 comprising providing to a human cell an inhibitor of a GATA 1, GATA 2, and/or GATA 3 transcription factor that binds at a GATA binding site selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and combinations thereof, in exon-1 in a human CCR3 gene thereby regulating CCR3 expression.